Aditya Bardia, a breast medical oncologist and physician scientist who specializes in developing novel targeted and personalized therapies, joined the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center, where he will assume several leadership roles across the institution.
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.
